Reversible cerebral vasoconstriction syndrome: A narrative review
Headache: The Journal of Head and Face Pain · 2026-05 · 66 (5) · 1162-1180
DOI: 10.1111/head.70048 ↗At a glance
Übersichtsarbeit in Headache: The Journal of Head and Face Pain, published online on 2026-03-28. Written by Ícaro Araújo de Sousa and 7 co-authors. Institution: Department of Neuroscience and Behavior Sciences, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. Major MEDLINE topics: Headache Disorders, Primary, Vasospasm, Intracranial, Vasoconstriction, Cerebrovascular Disorders. Cited 1 times so far (Crossref); 149 references. The full text is freely available (open access, CC BY 4.0). Funded by: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).
Abstract (original language)
Objectives/Background This review summarizes current insights into Reversible cerebral vasoconstriction syndrome (RCVS) diagnosis, management, and outcomes. RCVS is a cerebrovascular disorder characterized by recurrent thunderclap headaches and transient segmental vasoconstriction of cerebral arteries, typically resolving within 3 months.
Methods
A comprehensive database search was performed across MEDLINE (via PubMed), Embase, Scopus, and the Cochrane Library.
Results
Although often self‐limiting, RCVS may cause complications such as subarachnoid hemorrhage, ischemic stroke, and cerebral edema. Triggers include vasoactive substances, pregnancy, postpartum state, and physical or emotional stress. Differentiating RCVS from conditions like primary angiitis of the central nervous system, aneurysmal subarachnoid hemorrhage, and cerebral venous thrombosis is essential because clinical and imaging features may overlap, whereas treatments differ. Advances in neuroimaging, especially magnetic resonance angiography and vessel wall imaging, have enhanced diagnostic accuracy. Management focuses on eliminating triggers and symptomatic support. Calcium channel blockers are frequently used, although their impact on disease evolution remains uncertain.
Conclusion
Although most patients recover without major sequelae, chronic symptoms such as long‐term headaches and neuropsychological symptoms, including cognitive impairment, underscore the need for ongoing follow‐up and suggest a post‐RCVS syndrome. image
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Neuroscience and Behavior Sciences, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
- Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
- Department of Psychology, Faculty of Philosophy, Sciences and Letters, Medical School of Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil.
- Depatment of Neurology and Neurosurgery, Federal University of São Paulo, São Paulo, São Paulo, Brazil.
ORCID profiles: Ícaro Araújo de Sousa, Octávio Marques Pontes-Neto
Funding
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Cite
APA
de Sousa, Í. A., Machado, A. D. S., Veras, A. O., Goulart, T. O., Tatsuta, S. G., Gonçalves, T. A. P., Rocha, E., & Pontes-Neto, O. M. (2026). Reversible cerebral vasoconstriction syndrome: A narrative review. Headache: The Journal of Head and Face Pain, 66(5), 1162-1180. https://doi.org/10.1111/head.70048
Vancouver
de Sousa ÍA, Machado ADS, Veras AO, Goulart TO, Tatsuta SG, Gonçalves TAP, et al. Reversible cerebral vasoconstriction syndrome: A narrative review. Headache: The Journal of Head and Face Pain. 2026;66(5):1162-1180. doi:10.1111/head.70048
BibTeX
@article{deSousa2026,
author = {de Sousa, Ícaro Araújo and Machado, Abner da Silva and Veras, Arthur de Oliveira and Goulart, Thiago Oscar and Tatsuta, Sarah Galassi and Gonçalves, Trajano Aguiar Pires and Rocha, Eva and Pontes-Neto, Octávio Marques},
title = {Reversible cerebral vasoconstriction syndrome: A narrative review},
journal = {Headache: The Journal of Head and Face Pain},
year = {2026},
volume = {66},
number = {5},
pages = {1162--1180},
doi = {10.1111/head.70048}
}
EUVIMED